Preferences for HIV Preexposure Prophylaxis Products Among Black Women in the U.S

AIDS Behav. 2022 Jul;26(7):2212-2223. doi: 10.1007/s10461-021-03571-8. Epub 2022 Jan 5.

Abstract

In a nationwide sample of Black women in the U.S., we assessed preferences for HIV preexposure prophylaxis (PrEP) products, including long-acting injectable (LAI) PrEP and once-daily oral PrEP. Among 315 respondents, 32.1% were aware of PrEP and 40.6% were interested in using it; interest increased to 62.2% if PrEP were provided for free. Oral PrEP was the preferred option (51.1%), followed by LAI PrEP (25.7%), vaginal gel (16.5%), and vaginal ring (6.7%). When examining oral and LAI PrEP alone, most (62.7%) preferred oral PrEP. LAI PrEP was more likely to be preferred among respondents with concerns about healthcare costs or PrEP-related stigma, and among those who reported inconsistent condom use and multiple sexual partners. Although most Black women preferred oral PrEP, LAI PrEP may be appealing to a subset with social and structural barriers to PrEP use, such as cost and stigma, and those at increased risk of HIV infection.

Keywords: Black women; Cabotegravir; HIV prevention; Long-acting injectable (LAI); Preexposure prophylaxis (PrEP).

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Female
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • Homosexuality, Male
  • Humans
  • Male
  • Patient Acceptance of Health Care
  • Pre-Exposure Prophylaxis*

Substances

  • Anti-HIV Agents